Lexeo Therapeutics Advances LX2020 with FDA RMAT Designation
NEW YORK, August 5, 2026 Lexeo Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative...
fast track
Advertisement
Genprex and Roche Diagnostics Advance TROP2 Biomarker Strategy
Austin, Texas, August 3, 2026 Genprex, Inc. announced a collaboration with Roche Diagnostics to conduct biomarker assay validation studies...
Keenova Publishes New XIAFLEX Data in Peyronie’s Disease
Dublin, Ireland, August 3, 2026 Keenova Therapeutics plc announced the publication of a new manuscript evaluating XIAFLEX® (collagenase clostridium...
Acurx Gains FDA Guidance for Ibezapolstat Phase 3 Program
Staten Island, New York, August 3, 2026 Acurx Pharmaceuticals, Inc. announced further regulatory guidance from the U.S. Food and...
Cullinan Therapeutics Plans Registrational Phase 2 Trial for CLN-049
CAMBRIDGE, Mass., July 28, 2026 Cullinan Therapeutics announced positive feedback from the U.S. Food and Drug Administration (FDA) following...
Advertisements
Armata Advances AP-SA02 Toward Phase III Bacteremia Trial
LOS ANGELES, July 20, 2026 Armata Pharmaceuticals, Inc. has announced significant clinical, regulatory, manufacturing, and operational progress supporting the...
Ionis Reaches Phase 3 Enrollment Milestone for Obudanersen
CARLSBAD, Calif., July 6, 2026 Ionis Pharmaceuticals announced the completion of enrollment for the pivotal pediatric cohort of its...
Cadrenal Highlights Phase 2 CAD-1005 Trial in Prestigious ISTH 2026 Session
PONTE VEDRA, Fla., June 24, 2026 Cadrenal Therapeutics, Inc. announced that late-breaking clinical data from its Phase 2 study...
CeleCor Submits FDA NDA for Zalunfiban After Phase 3 Success
DEL MAR, Calif., June 24, 2026 CeleCor Therapeutics announced the completion of its New Drug Application (NDA) submission to...
Enterome Wins FDA Orphan Tag for EO2463 in iNHL
Paris, France | May 28, 2026 Enterome announced that the U.S. FDA has granted Orphan Drug Designation (ODD) to...
Advertisement
